Suppr超能文献

嵌合抗原受体T细胞疗法治疗中枢神经系统自身免疫性疾病:系统文献综述

Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review.

作者信息

Konitsioti Agni M, Prüss Harald, Laurent Sarah, Fink Gereon R, Heesen Christoph, Warnke Clemens

机构信息

Department of Neurology, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.

Faculty of Medicine, University Hospital Cologne, Cologne, Germany.

出版信息

J Neurol. 2024 Oct;271(10):6526-6542. doi: 10.1007/s00415-024-12642-4. Epub 2024 Sep 14.

Abstract

IMPORTANCE

B-cell-targeting monoclonal antibodies have demonstrated safety and efficacy in multiple sclerosis or anti-aquaporin-4 IgG positive neuromyelitis optica spectrum disorder. However, these therapies do not facilitate drug-free remission, which may become possible with cell-based therapies, including chimeric antigen receptor (CAR) T cells. CAR T-cell therapy holds promise for addressing other antibody-mediated CNS disorders, e.g., MOG-associated disease or autoimmune encephalitis.

OBJECTIVE

To provide an overview of the current clinical knowledge on CAR T-cell therapy in central nervous system autoimmunity.

EVIDENCE REVIEW

We searched PubMed, Embase, Google Scholar, PsycINFO, and clinicaltrials.gov using the terms 'CAR T cell' and 'multiple sclerosis/MS' or 'neuromyelitis optica/spectrum diseases/NMOSD' or 'MOG-associated disease/MOGAD 'or' autoimmune encephalitis' or 'neuroimmunology'.

FINDINGS

An ongoing phase I clinical trial has indicated the safety and benefits of anti-BCMA CAR T cells in 12 patients with AQP4-IgG seropositive neuromyelitis optica spectrum disorder. Case reports involving two individuals with progressive multiple sclerosis and one patient with stiff-person syndrome demonstrated a manageable safety profile following treatment with anti-CD19 CAR T cells. Recruitment has commenced for two larger studies in MS, and a phase I open-label basket study is underway to evaluate BCMA-directed CAR T cells in various antibody-associated inflammatory diseases, including MOG-associated disease. Preclinical research on NMDA receptor antibody autoimmune encephalitis treated with chimeric autoantibody receptor T cells generated promising data.

CONCLUSIONS AND RELEVANCE

There is minimal evidence of the benefits of CAR T-cell therapy in individuals with central nervous system-directed autoimmunity. Nevertheless, multicenter controlled clinical trials with a manageable safety profile appear feasible and are warranted due to very promising case experiences.

摘要

重要性

靶向B细胞的单克隆抗体已在多发性硬化症或抗水通道蛋白4 IgG阳性视神经脊髓炎谱系障碍中显示出安全性和有效性。然而,这些疗法并不能促进无药物缓解,而基于细胞的疗法,包括嵌合抗原受体(CAR)T细胞,可能会实现这一点。CAR T细胞疗法有望解决其他抗体介导的中枢神经系统疾病,例如MOG相关疾病或自身免疫性脑炎。

目的

概述目前关于CAR T细胞疗法治疗中枢神经系统自身免疫性疾病的临床知识。

证据综述

我们使用“CAR T细胞”和“多发性硬化症/ MS”或“视神经脊髓炎/谱系疾病/ NMOSD”或“MOG相关疾病/ MOGAD”或“自身免疫性脑炎”或“神经免疫学”等术语检索了PubMed、Embase、谷歌学术、PsycINFO和clinicaltrials.gov。

研究结果

一项正在进行的I期临床试验表明,抗BCMA CAR T细胞对12例AQP4-IgG血清阳性视神经脊髓炎谱系障碍患者具有安全性和益处。涉及两名进行性多发性硬化症患者和一名僵人综合征患者的病例报告显示,接受抗CD19 CAR T细胞治疗后,安全性可控。两项针对MS的更大规模研究已开始招募患者,一项I期开放标签篮式研究正在进行中,以评估BCMA导向的CAR T细胞在包括MOG相关疾病在内的各种抗体相关炎症性疾病中的作用。用嵌合自身抗体受体T细胞治疗NMDA受体抗体自身免疫性脑炎的临床前研究产生了有前景的数据。

结论与意义

关于CAR T细胞疗法对中枢神经系统自身免疫性疾病患者的益处,证据极少。然而,鉴于非常有前景的病例经验,开展安全性可控的多中心对照临床试验似乎是可行的,也是必要的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8d8/11446985/9c117b2a777b/415_2024_12642_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验